

Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Lung Committee

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer:..... Anne Chiang, MD, PhD
 Statisticians: Yingqi Zhao, PhD
 Mary Redman, PhD
 Mia Hsieh, MS
 Katie Minichiello, MS
 James Moon, MS
 Sara Threlkel, BS

Scientific Leadership

Translational Medicine:
 Biology/Pathology Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging:..... Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology:..... Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease:..... Raymond Osarogiagbon, MD
 Eric Miguel Toloza, MD, PhD
 Locally Advanced Disease:..... Mary B. Daly, MD
 Tina Cascone, MD, PhD
 Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Rachel E. Sanborn, MD
 Sarah B. Goldberg, MD
 Community Engagement:..... Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 Veterans Affairs: Chao H. Huang, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals: Lisa G. Davis, RN
 Patient Advocate:..... Barbara Martin
 Pharmaceutical Science:..... Joyce Lee, PharmD
 Safae Ghouraihi, PharmD
 Protocol Project Managers: Justine Trevino
 Gabe Chadwell (Lung-MAP)
 Sr. Protocol Project Manager:..... Jennifer Beeler, MA (Lung-MAP)

Clinical Trials Program Manager:..... Sarah Cantu
 Crystal Miwa (Lung-MAP)

Time/Location

Saturday, May 2, 2026 9:30 a.m. - 12:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

General Update & Accruals: Jhanelle E. Gray, MD

Upcoming Meetings and Deadlines

Accruals, Abstracts, and Publications

Thoracic Surgery Session: Eric Toloza, MD, PhD

Thoracic Radiation Session: Megan Daly, MD

Translational Medicine Session: Ignacio Wistuba, MD

Community Engagement: Paul J. Hesketh, MD & Lucy Gansauer, MSN, RN

Thoracic Medical Oncology: Jhanelle Gray, MD

S2409, "PRISM: A Multicohort PReclison SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Activated: 9/8/25; Accrual Goal: 900; Accrual: 21. Anne Chiang, MD and Alberto Chiappori

S2414 "A randomized phase III trial incorporating pathologic response in participants with early stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting (INSIGHT)". Activated: 3/14/25; Accrual Goal: 306; Accrual: 3. Jeremy Cetnar, MD, MS and Raymond Osarogiagbon, MD

CTIU2317/S2402, "Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer (PROSPECT LUNG)." Activated: 12/11/24; Accrual Goal: 1100. Accrual: 8. Raid Aljumaily, MD and Raymond Osarogiagbon, MD

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3937. Karen Reckamp, MD and David R. Gandara, MD

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Lung Committee

(Lung-MAP Non-Matched Sub-Study).” Activated: 4/28/25; Accrual Goal: 378; Accrual: 69. Saiama Waqar, MD, MSCI and Tina Li, MD

S1900J, “A Phase II Study of Amivantamab SC in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with High MET Amplification (Lung-MAP Sub-Study).” Activated: 9/27/24; Accrual goal: 88; Accrual: 12; 4 (revision 1). Shirish Gadageel, MD and Christian Rolfo, MD

S1900G, “A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study).” Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 31; 24 (revision 1). Sarah Goldberg, MD, MPH and Ross Camidge, MD, PhD

S1900K, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Activated: 12/18/2023; Accrual Goal: 56; Accrual: 24. Paul Paik, MD and Xiuning Le, MD, PhD

Open Discussion

Active Studies

LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).” Drs. Reckamp, Waqar, Redman, et al. Activation: 1/28/19.

S1900G, “A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, “A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Paik and Le. Activation: 12/18/23.

S1900J, “A Phase II Study of Amivantamab Hyaluronidase in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Rolfo and Gadageel. Activation: 9/27/24.

S1800E, “A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Waqar and Li. Activation: 4/28/25.

S2409, “PRISM: PReclision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC).” Drs. Chiang, Chiappori, Kim, et al. Activation: 9/8/25.

S2414, “A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT).” Drs. Cetnar and Osarogiagbon. Activation: 3/14/25.

CTSU/A081801, “Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO).” Dr. Gray. Activation: 6/3/20.

CTSU/A151216, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activation: 8/18/14.

CTSU/EA5182, “Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC).” Dr. Goldberg. Activated:10/22/20.

CTSU/NRG-LU007, “Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial.” Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, “Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer.” Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, “A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).” Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1

Lung Committee

- Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.
- S1900A**, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.
- S1900B**, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.
- S1900C**, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.
- S1900E**, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21. Permanently closed: 12/27/24.
- S1900F**, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.
- S1929**, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.
- S1934**, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.
- CTSU/EA5163/S1709**, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19. ; Closed to accrual: 3/1/24.
- S1701**, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18; Closed to accrual: 10/15/22.
- S1827**, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20. Permanently closed to accrual: 12/15/25.
- S1914**, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20. Closed to accrual: 9/6/24.
- S1933**, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20. Permanently closed to accrual: 2/15/26.
- S2302**, "PRAGMATICA: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer" Drs. Reckamp and Dragnev. Activation: 3/6/23; Closed to accrual: 12/20/24.
- CTSU/E4512**, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14; Closed to accrual: 5/10/24.
- CTSU/EA5181**, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20; Closed to accrual: 11/20/23.
- CTSU/NRG-LU002**, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21; Closed to accrual: 12/06/23.
- CTSU/NRG-LU005**, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation

Lung Committee

Plus Atezolizumab.” Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22; Closed to accrual: 12/31/23.

CTSU/EA5191, “A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.” Dr. Massarelli. Activated: 5/22/20; Closed to accrual: 10/13/23.

NCI-Approved Concepts

S1900N, “A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Drs. Scott and Riess.

S2404, “Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations” Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900P, “A Phase II Study of Sapanisertib Plus Serabelisib Plus Paclitaxel Versus Standard of Care Chemotherapy in Participants with NFE2L2, KEAP1 or PI3K Pathway-Positive Stage IV Squamous Cell Lung Cancers (ECOG-ACRIN Lung-MAP Sub-Study).” Drs. Paik and Riano.

S1900Q, “A Phase II Study of Zongertinib and Trastuzumab Deruxtecan in Participants with HER2-Positive Stage IV Non-Small Cell Lung Cancer (Alliance Lung-MAP Sub-Study).” Drs. Parikh and Doroshow.

S2608, “Sequencing of Immunotherapy and Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Randomized Phase III Study (SIMON).” Dr. Park.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1827 Prophylactic Cranial Irradiation for Patients With SCLC – A New Perspective in the Immunotherapy Era (BRIEF REPORT). Levy A, Rusthoven CG, Brown PD, Le Péchoux C, Faivre-Finn C. *J Thorac Oncol*. 2025 Mar;20(3):395-398. doi: 10.1016/j.jtho.2024.11.011. Epub 2024 Nov 15. <https://pubmed.ncbi.nlm.nih.gov/39551470/>

CTIU2317-A082304-S2402 PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. A Booth, S Hillman, K Laumann, YQ Zhao, M LeBlanc, K Chansky, S Giri, J Dill, J Johnson, K Kelley, L Martin. *Journal of Thoracic Oncology*. 2026. p.103650. <https://pubmed.ncbi.nlm.nih.gov/41747891/>

A221504 Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. P Gupta, K Gupta, T Dockter, E Harlos, S Chow, N Subbiah, K Ruddy, L Bazhenova, S Terstriep, C Huang, R Kratzke, E Vokes, C Loprinzi. *Cancers*. 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373. <https://pubmed.ncbi.nlm.nih.gov/41681846/>

Submitted Manuscripts

S0424 Exposures, Tumor Factors and Survival by Sex and Smoking Status in Non-Small Cell Lung Cancer. A Prospective Case-Series Trial (SWOG S0424, NCI NCTN). K Albain, J Moon, C Ambrosone, A Darke, M Hsieh, R Santella, TYD Cheng, W Holland, A Borczuk, CH Chay, PT Morris, E Vallieres, R Kratzke, JR Molina, JM Kolesar, Y Chen, S Matsumoto, M Reid, G Zirpoli, W Davis, R Ondracek, W Bshara, A Omilian, J Gray, K Kelly, PN Lara, M Redman, D Gandara, P Mack. Submitted 2025.

Lung-MAP Defining Resistance to Immune Checkpoint Inhibitor Therapy in Clinical Trials – A Consensus Statement from Lung-MAP. D Doroshow, et al. Submitted 2025.

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914
Arnot Ogden Medical Center/Falck Cancer Center	7	-	-	-	-	-	-	3
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	44	2	3	2	-	-	1	10
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	5	-	-	-	-	-
Boston Medical Center	-	-	7	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	2	2	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	4	-	-	-	-	-	-	7
Cancer Research for the Ozarks NCORP	52	-	-	-	-	-	-	9
Cancer Research of Wisconsin and Northern Michigan Consortium	39	-	7	4	-	-	-	8
Carle Cancer Center NCI Community Oncology Research Program	3	-	1	1	-	-	-	6
Carolinas Medical Center/Levine Cancer Institute	-	-	2	-	-	-	-	-
Cedars-Sinai Medical Center	21	-	-	1	1	-	-	4
City of Hope Comprehensive Cancer Center	5	-	1	-	-	-	-	-
Columbia University Minority Underserved NCORP	13	-	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	28	-	6	-	-	-	-	-
CommonSpirit Health Research Institute	39	-	1	-	-	-	-	1
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	2	-	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	18	-	-	-	-	-	-	3
Fred Hutchinson Cancer Research Center LAPS	6	-	-	-	2	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	2	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	1	-	-	-	-	2
Georgia NCI Community Oncology Research Program	75	2	3	1	-	-	-	9
Grupo Oncologico Cooperativo de Investigacion	-	-	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	20	-	3	-	-	-	-	3
Hartford Hospital	3	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	29	-	2	-	-	1	-	-
Heartland Cancer Research NCORP	156	1	9	6	-	-	-	40
Henry Ford Hospital	20	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	8	-	-	-	-	-
Intermountain Medical Center	1	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	93	-	-	8	-	-	1	3
Kansas City Veterans Affairs Medical Center	3	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	35	-	-	-	-	-	-	4
Loma Linda University Medical Center	6	-	-	-	-	-	-	-
Loyola University Medical Center	26	-	-	-	-	-	-	1
Malcom Randall Veterans Administration Medical Center	22	1	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	65	-	4	1	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	25	-	-	2	1	-	-	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	129	1	4	7	2	-	-	12
Mission Hospital	1	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1800E	S1827	S1900E	S1900G	S1900J	S1900K	S1914
Moffitt Cancer Center	21	1	1	1	1	-	-	-
Montana Cancer Consortium NCORP	10	-	1	1	-	-	-	1
Mount Sinai Hospital	-	-	-	-	-	-	-	9
NCORP of the Carolinas (Prisma Health NCORP)	20	-	-	1	-	-	-	-
National Cancer Center-Korea	-	-	1	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	15	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	115	-	1	2	-	-	-	8
Northwell Health NCORP	-	-	-	-	-	-	-	1
Northwestern University LAPS	31	1	1	-	2	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	1	-
Oregon Health and Science University	13	-	-	-	1	-	1	1
Our Lady of the Lake Hospital	4	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	23	-	-	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-	-
Salem Hospital	7	-	-	2	-	-	-	-
South Sound Care Foundation	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	56	-	8	1	-	-	1	14
Sutter Cancer Research Consortium	79	-	-	1	1	-	-	-
The Don and Sybil Harrington Cancer Center	13	-	-	1	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	48	3	1	2	1	-	-	11
UC Irvine Health/Chao Family Comprehensive Cancer Center	32	1	1	-	-	-	-	5
UC San Diego Moores Cancer Center	17	1	-	1	-	-	-	-
UPMC Hillman Cancer Center LAPS	91	2	12	7	-	-	-	2
USC Norris Comprehensive Cancer Center LAPS	-	-	7	-	-	-	-	7
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	-	-	-	-	17
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	15	-	4	-	1	1	1	6
University of Kansas Cancer Center - MCA Rural MU NCORP	109	3	1	1	-	-	-	-
University of Kentucky/Markey Cancer Center	58	3	1	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	35	1	1	-	-	-	-	6
University of Rochester LAPS	66	-	-	6	-	-	1	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	7	-	-	-	-	6
University of Utah - Huntsman Cancer Institute LAPS	2	1	4	-	-	-	1	5
Upstate Carolina Consortium Community Oncology Research Program	42	-	3	-	-	-	-	3
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	44	-	4	1	-	-	-	13
Yale University - Yale Cancer Center LAPS	32	2	5	3	4	-	-	11
ALLIANCE	916	14	29	21	3	1	4	42
CCTG	-	-	39	-	-	-	-	-
ECOG-ACRIN	382	5	11	19	-	-	6	31
NRG	522	4	89	12	3	-	-	91
Total	3,857	49	304	118	23	3	18	417

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1933	S2302	S2402	S2414	A081801	A082002	A151216	EA5162
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	1	-	1	-
Banner University Medical Center - Tucson	-	2	-	-	-	-	7	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	1	16	1	1	4	-	26	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	3	-
CWRU Case Comprehensive Cancer Center LAPS	-	18	-	-	21	-	59	-
Cancer Research Consortium of West Michigan NCORP	-	3	-	-	-	-	1	-
Cancer Research for the Ozarks NCORP	4	5	-	-	-	-	1	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	8	-	1	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	8	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	21	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	9	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	-	-	-	-	5	-
Columbia University Minority Underserved NCORP	1	7	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	4	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	1	-	-	-	-	2	-
Corewell Health William Beaumont University Hospital	-	-	-	-	-	-	2	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-	-	-	3	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	8	-
Duke University - Duke Cancer Institute LAPS	-	2	-	1	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	10	-	-	-	-	15	3
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	18	-	-	-	-	10	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	7	1	-	1	-	1	-
Hartford Hospital	-	4	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	7	-	-	-	-	-	-
Heartland Cancer Research NCORP	5	52	-	-	-	-	-	-
Henry Ford Hospital	1	-	-	-	2	-	44	1
Houston Methodist Hospital	-	2	-	-	-	-	8	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	1	-	3	-
Kaiser Permanente NCI Community Oncology Research Program	-	27	-	-	6	-	208	-
Kansas City Veterans Affairs Medical Center	-	1	-	-	-	-	-	-
Lahey Hospital and Medical Center	2	12	-	1	1	-	30	-
Loma Linda University Medical Center	-	-	-	-	-	-	10	-
Loyola University Medical Center	-	8	-	-	-	-	26	-
Malcom Randall Veterans Administration Medical Center	-	4	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	9	-	-	13	-	34	-
Medical University of South Carolina Minority Underserved NCORP	-	19	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	18	-	-	-	-	11	-
Mission Hospital	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1933	S2302	S2402	S2414	A081801	A082002	A151216	EA5162
Moffitt Cancer Center	-	52	-	-	28	-	83	-
Montana Cancer Consortium NCORP	1	1	-	-	-	-	-	-
Mount Sinai Hospital	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	1	-
National Cancer Center-Korea	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	1	3	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	1	-	3	-
Northwestern University LAPS	-	18	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	6	-	-	-	-	-	-
Oregon Health and Science University	-	3	-	-	8	-	24	-
Our Lady of the Lake Hospital	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	-	-	-	-	4	-
Regents of the University of Michigan	-	6	-	-	-	-	51	-
Salem Hospital	-	-	-	-	-	-	-	-
South Sound Care Foundation	-	3	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	7	-	1	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	1	1	11	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-	-	-	5	-
UC Davis Comprehensive Cancer Center LAPS	-	15	-	-	1	2	46	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	-	-	-	15	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	5	-
UPMC Hillman Cancer Center LAPS	5	10	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	3	-	-	-	-	12	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	12	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	12	-	-	-	-	3	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	24	-
University of Colorado Cancer Center LAPS	-	3	-	-	2	-	58	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	5	-	-	1	-	31	-
University of Kentucky/Markey Cancer Center	-	9	-	-	-	1	5	-
University of Mississippi Medical Center	-	-	-	-	-	-	26	-
University of Nebraska Medical Center	-	-	-	-	1	-	-	-
University of Oklahoma Health Sciences Center LAPS	18	10	3	-	-	-	-	-
University of Rochester LAPS	-	14	1	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	1	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	2	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	10	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	1	-
Western States Cancer Research NCORP	-	-	-	-	-	-	1	-
Wisconsin NCI Community Oncology Research Program	-	5	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	14	-	-	7	-	57	-
ALLIANCE	5	154	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	90	-	-	-	-	-	-
NRG	2	55	-	-	-	-	-	-
Total	47	838	6	5	101	4	986	4

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA5182	EA5221	EA5231	NRGLU008
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	2	-	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	1	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Corewell Health William Beaumont University Hospital	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hartford Hospital	1	-	1	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Houston Methodist Hospital	2	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-
Intermountain Medical Center	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	8	-	-	-
Kansas City Veterans Affairs Medical Center	-	1	-	-
Lahey Hospital and Medical Center	-	-	-	-
Loma Linda University Medical Center	-	-	-	-
Loyola University Medical Center	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Mission Hospital	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA5182	EA5221	EA5231	NRGLU008
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
Mount Sinai Hospital	8	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-
National Cancer Center-Korea	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-
Oregon Health and Science University	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	-	-
Regents of the University of Michigan	-	-	-	-
Salem Hospital	-	-	-	-
South Sound Care Foundation	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	3
The Don and Sybil Harrington Cancer Center	-	-	-	-
The James Graham Brown Cancer Center at University of Louisville	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-
University of Arkansas for Medical Sciences	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-
University of Mississippi Medical Center	-	-	-	-
University of Nebraska Medical Center	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-
University of Rochester LAPS	-	2	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-
Western States Cancer Research NCORP	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	25	4	1	5

